Study of Safety and Immunogenicity of BVRS-GamVac-Combi
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the
first Middle East respiratory syndrome (MERS) outbreak. MERS-CoV causes an acute
lower-respiratory infection in humans, with a fatality rate of ~34.5%.
The aim of the study is to assess the safety and immunogenicity of heterologous
adenoviral-based vaccine against MERS - BVRS-GamVac-Combi.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation